News Related to Janux Therapeutics

Related coverage linked through entity extraction aliases.

Janux Therapeutics Doses First Patient in Phase 1 Trial of JANX011 for Autoimmune Diseases

Feb 17, 2026

Janux Therapeutics has dosed the first participant in a Phase 1 clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform for autoimmune disease treatment.

Metastatic Prostate Cancer Clinical Trial Pipeline Expands with Multiple New Studies

Feb 14, 2026

Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.